Found 24 matching trials
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) N/A The primary objectives of the study are to estimate the risk of major conge...
Show More Location
University of Colorado Anschutz Medical Campus
Learn More & Join Trial
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity) N/A The investigators propose a multi-center pilot study, which aims to evaluat...
Show More Status
Active Not Recruiting
Location
University of Colorado, Denver
Learn More & Join Trial
Study of Diroximel Fumarate in the Real-World Setting N/A The primary objective of the study is to characterize the persistence to th...
Show More Location
Regina Berkovich MD Phd Inc
Learn More & Join Trial
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) PHASE3 In this study, researchers will learn more about the study drugs diroximel ...
Show More Location
Multiple Locations
Learn More & Join Trial
Improving the Effect of Multiple Sclerosis Drugs by Chronobiology NA A trial for evaluating the ability to improve the effect of dimethyl fumara...
Show More Location
Hadassah Medical Center
Learn More & Join Trial
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS PHASE4 The DELIVER-MS study seeks to answer the question: Does early treatment wit...
Show More Status
Active Not Recruiting
Location
University of Colorado-Anschutz Medical Campus
Learn More & Join Trial
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) PHASE2 In this study, researchers will learn more about a study drug called BIIB09...
Show More Location
HonorHealth Neurology
Learn More & Join Trial
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial NA FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) tar...
Show More Status
Active Not Recruiting
Location
University of Alabama at Birmingham
Treatments Being Tested
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod Learn More & Join Trial
Exploring Diroximel Fumarate Real-world Experience in Canada and Israel N/A The primary objective of the study is to characterize the persistence to th...
Show More Location
Lady Davis Carmel Medical Center
Learn More & Join Trial
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) PHASE3 Multiple sclerosis (MS) is a chronic disease of the central nervous system ...
Show More Location
CHU de Bordeaux-Hôpital Pellegrin
Learn More & Join Trial